Combatting COVID’s impact on mental health through building community at Osmind
21% of Americans will be clinically depressed at some point in their life. Sadly, ⅓ of all depressed people have treatment-resistant depression (TRD). Even though treatment resistance is such a big problem, it seems like most mental health organizations neglect these populations. At Osmind, we don’t. We are committed to improving mental health care for those who need it most, especially during the era of COVID-19.
Today, to kickoff of Mental Health Awareness month, we are launching an online community focused on treatment-resistant depression (TRD), related mental health disorders, and FDA-approved psychedelic medicine. Free for everyone, the community connects people who struggle with mental health, medical professionals, scientific researchers, academics, advocates, caregivers, and more.
Our first-of-its-kind online community fills a pressing need especially during COVID-19, which has made mental health services and human-to-human connection even more important. We are offering a free directory of TRD clinics and the services they offer during the pandemic (e.g. in-person care, telemedicine, e-prescribing). We also bring in special guests who join the community to do Ask-Me-Anything (AMA) events, post content, and answer questions. We had our first AMA by a psychedelic medicine expert from Stanford University Medical Center. Our AMAs happen every Wednesday with experts in the field. We also provide wikis written by MDs on the Osmind team that provide unbiased, evidence-based information and collaborative wikis collectively written by Community members as people contribute their own valuable experiences and perspectives.
We aim to provide a safe space for people to ask for support when they need it and to provide support when others need it. We want people to discuss — without judgment — treatments that can help heal those who have not gotten better from other therapies. These promising treatments include traditional psychiatric approaches, interventional approaches using various types of brain stimulation, and an emerging class of therapeutic strategies called psychedelic medicine. Psychedelic medicine includes ketamine and esketamine (which are FDA approved), MDMA-assisted psychotherapy (currently in phase 3 trials with FDA Breakthrough Status and Expanded Access), psilocybin-assisted psychotherapy (currently in phase 2 trials with FDA Breakthrough Status), and many other treatments currently in development.
Our team started as a pair of Stanford University graduate and medical students. We’ve since grown to include a diverse group of individuals tied together by our shared mission to improve mental health. Some of our friends, family members, advisors, and team members have had depression and know first-hand how difficult things can be while feeling sad and alone. Some of us have gone through severe depression that was refractory to multiple lines of antidepressants, before finally being helped by innovative treatments like ketamine. As a result, our team is deeply mission-driven and impact-oriented.
We’re based out of Palo Alto, California. Committed to improving mental health care for those who need it most, we’re building a community and care platform for people with treatment resistant mental health disorders and their providers. The Osmind Platform enables measurement-based care to further research of life-changing treatments including psychedelic medicine, interventional psychiatry, and other psychiatric approaches.
Drop us a line at email@example.com to learn more!